U.S. Markets close in 3 hrs 6 mins

Morphosys AG (MOR.DE)

XETRA - XETRA Delayed Price. Currency in EUR
Add to watchlist
71.00+1.36 (+1.95%)
At close: 5:35PM CEST

Morphosys AG

Semmelweisstrasse 7
Planegg 82152
Germany
49 89 89927 0
http://www.morphosys.com

SectorHealthcare
IndustryBiotechnology
Full Time Employees344

Key Executives

NameTitlePayExercisedAge
Mr. Jens H. HolsteinChief Financial Officer and Member of Management BoardN/AN/AN/A
Dr. Marlies SprollChief Scientific Officer (Leave of Absence) and Member of Management BoardN/AN/A59
Dr. Malte PetersChief Devel. Officer and Member of Management BoardN/AN/A55
Mr. Klaus De WallHead of Accounting & TaxN/AN/AN/A
Mr. Sascha AllilovicHead of Corp. Fin. and Corp. Devel.N/AN/AN/A
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.

Description

MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation. Its product pipeline includes MOR208, a humanized monoclonal antibody that targets the antigen CD19, which is in Phase II clinical trials for the treatment of B cell malignancies; and MOR202, a human monoclonal HuCAL-antibody directed against CD38, which is in Phase I/IIa trials for the treatment of multiple myeloma and various leukemias. The company’s product pipeline also comprises MOR103, a human HuCAL-antibody directed against granulocyte-macrophage colony-stimulating factor that is in Phase II clinical trials for treating rheumatoid arthritis; and MOR209/ES414, a bi-specific anti-PSMA/anti-CD3 antibody against prostate cancer that is in Phase I clinical trials for the treatment of metastatic castration-resistant prostate cancer. In addition, its product pipeline includes MOR106, a human monoclonal IL-17C antibody, which is in Phase I clinical trials for the treatment of atopic dermatitis; and MOR107, a novel lanthipeptide that is in Phase I clinical trials for the treatment of fibrotic diseases. The company was founded in 1992 and is headquartered in Planegg, Germany.

Corporate Governance

Morphosys AG’s ISS Governance QualityScore as of September 1, 2017 is 3. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 1; Compensation: 4.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.